Large Bluejay Diagnostics (BJDX) holder reports full exit in 13G/A

Rhea-AI Filing Summary

Bluejay Diagnostics, Inc. (BJDX) now has one less significant shareholder after Braeden Lichti and Northstrive Fund II LP fully exited their position in its common stock. As of June 2, 2026, both reporting persons beneficially own 0 shares, representing 0.00% of the outstanding common stock.

The amendment notes that all previously held shares of Bluejay Diagnostics’ common stock were sold, and the filers ceased to be beneficial owners of more than five percent of the company’s shares. This amendment is described as the final amendment and an exit filing for both reporting persons.

Insights

Equity ownership and disclosure analyst

A former 5%+ holder has fully exited Bluejay Diagnostics.

The amendment shows that Braeden Lichti and Northstrive Fund II LP have disposed of all Bluejay Diagnostics common shares they previously reported, reducing their beneficial ownership to 0 shares and 0.00% of the class as of June 2, 2026.

This filing is characterized as a final amendment and exit filing, meaning these parties are no longer required to report as 5% beneficial owners. The business activities and backgrounds of the reporting persons are restated, but no new financing, earnings, or operational developments for Bluejay Diagnostics are disclosed here.

Key Figures

Beneficial ownership shares: 0 shares Percent of class owned: 0.00% Date of event: June 2, 2026 +2 more

5 metrics

Beneficial ownership shares 0 shares Beneficially owned by each reporting person as of Amendment

Percent of class owned 0.00% Percent of Bluejay Diagnostics common stock class after disposition

Date of event June 2, 2026 Date reporting persons ceased to be 5% beneficial owners

Par value per share $0.0001 per share Par value of Bluejay Diagnostics common stock

CUSIP 095633608 CUSIP for Bluejay Diagnostics common stock

Key Terms

beneficial owner, Schedule 13G, exit filing, sole voting power, +1 more

5 terms

beneficial owner financial

"As of June 2, 2026, the Reporting Persons ceased to be beneficial owners of more than five percent of the Issuer's outstanding Common Stock."

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

Schedule 13G regulatory

"This Amendment No. 1 relates to the Common Stock of the Issuer and amends the Schedule 13G."

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

exit filing regulatory

"Accordingly, this filing is the final amendment to the and constitutes an exit filing for the Reporting Persons."

sole voting power financial

"Sole power to vote or to direct the vote: Braeden Lichti: 0 shares Northstrive Fund II LP: 0 shares"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

dispositive power financial

"Sole power to dispose or to direct the disposition of: Braeden Lichti: 0 shares Northstrive Fund II LP: 0 shares"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

Bluejay Diagnostics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

095633608

(CUSIP Number)

Ross. D. Carmel, Esq.
1185 Avenue of the Americas, 26th Floor
New York, NY, 10036
(212) 930-9700

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

06/02/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 095633608

1

Name of reporting person

Braeden Lichti

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CANADA (FEDERAL LEVEL)

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.00 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

On June 2, 2026, Mr. Lichti sold all of his previously owned shares of the Issuer's common stock and no longer beneficially owns any shares of common stock of the Issuer. Accordingly, this filing is the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Person.

SCHEDULE 13D

CUSIP Number(s): 095633608

1

Name of reporting person

Northstrive Fund II LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.00 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Braeden Lichti is, as of the date of this Schedule 13D, the Manager of Northstrive Fund II LP ("Northstrive Fund"). On June 2, 2026, Northstrive Fund sold all of its previously owned shares of the Issuer's common stock and no longer beneficially owns any shares of common stock of the Issuer. Accordingly, this filing is the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Persons.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.0001 per share
(b)	Name of Issuer: Bluejay Diagnostics, Inc.
(c)	Address of Issuer's Principal Executive Offices: 360 Massachusetts Avenue, Suite 203, Acton, MASSACHUSETTS , 01720.
Item 1 Comment: Mr. Braeden Lichti and Northstrive Fund previously filed a Schedule 13D on March 11, 2026. This Amendment No. 1 relates to the Common Stock of the Issuer and amends the Schedule 13G. The principal executive offices of the Issuer are located at 360 Massachusetts Avenue, Suite 203, Acton, MA 01720.
Item 2.	Identity and Background
(a)	Mr. Lichti serves as the Manager of Northstrive Fund. As of the date of this Amendment, neither Reporting Person beneficially owns any shares of the Issuer's Common Stock, as reflected on the cover pages and in Item 5.
(b)	The address of each of the Reporting Persons is 120 Newport Center Drive, Newport Beach, CA 92660.
(c)	Northstrive Fund is principally engaged in the business of investments into private and public securities. Mr. Lichti is principally engaged as the Chief Executive Officer of Northstrive Companies Inc., a California based management, advisory and investment company.
(d)	Mr. Lichti has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors).
(e)	None of the Reporting Persons have, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.
(f)	Northstrive Fund is a Delaware limited partnership. Mr. Lichti is a citizen of Canada.
Item 3.	Source and Amount of Funds or Other Consideration
	Not applicable. This Amendment reports only the disposition of all shares previously reported on the Schedule 13D and no additional securities were acquired since the Schedule 13D filed with the SEC on March 11, 2026 As of the date of this Amendment, the Reporting Persons beneficially own 0 shares of the Issuer's Common Stock.
Item 4.	Purpose of Transaction
	Since the filing of the Reporting Persons' Schedule 13D with the SEC on March 11, 2026, the Reporting Persons have disposed of all shares of common stock of the Issuer. As of June 2, 2026, the Reporting Persons no longer beneficially own any shares of the Issuer's Common Stock.
Item 5.	Interest in Securities of the Issuer
(a)	As of the date of this Amendment, the Reporting Person do not beneficially own any shares of the Issuer's common stock. The information set forth on the cover pages of this Amendment is incorporated herein by reference.
(b)	Sole power to vote or to direct the vote: Braeden Lichti: 0 shares Northstrive Fund II LP: 0 shares Shared power to vote or to direct the vote: Braeden Lichti: 0 shares Northstrive Fund II LP: 0 shares Sole power to dispose or to direct the disposition of: Braeden Lichti: 0 shares Northstrive Fund II LP: 0 shares Shared power to dispose or to direct the disposition: Braeden Lichti: 0 shares Northstrive Fund II LP: 0 shares
(c)	The information set forth in Item 3 above is incorporated herein by reference.
(d)	Not applicable.
(e)	As of June 2, 2026, the Reporting Persons ceased to be beneficial owners of more than five percent of the Issuer's outstanding Common Stock. This Amendment is the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Persons.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	The information in Items 3 and 4 is incorporated herein by reference.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Braeden Lichti

Signature:	/s/ Braeden Lichti
Name/Title:	Braeden Lichti
Date:	06/02/2026

Northstrive Fund II LP

Signature:	/s/ Braeden Lichti
Name/Title:	Braeden Lichti/Manager
Date:	06/02/2026

FAQ

What does the latest Schedule 13G/A say about BJDX ownership by Braeden Lichti and Northstrive Fund II?

The amendment states that Braeden Lichti and Northstrive Fund II LP now beneficially own 0 shares of Bluejay Diagnostics common stock, or 0.00% of the class, after selling all previously reported holdings as of June 2, 2026.

Who are the reporting persons in the Bluejay Diagnostics (BJDX) Schedule 13G/A exit filing?

The reporting persons are Braeden Lichti and Northstrive Fund II LP. Lichti is Manager of Northstrive Fund II LP and CEO of Northstrive Companies Inc., while Northstrive Fund II LP is a Delaware limited partnership investing in private and public securities.

When did Braeden Lichti and Northstrive Fund II cease to be 5% beneficial owners of BJDX?

They ceased to be beneficial owners of more than five percent of Bluejay Diagnostics’ common stock as of June 2, 2026. On that date, they had disposed of all previously owned shares and reported beneficial ownership of 0 shares and 0.00% of the class.

What is the purpose of this Bluejay Diagnostics (BJDX) Schedule 13G/A Amendment No. 1?

The amendment reports the disposition of all previously reported shares of Bluejay Diagnostics common stock by the reporting persons. It confirms that they no longer beneficially own any shares and specifies that this is the final amendment and an exit filing for them.

Where are the principal executive offices of Bluejay Diagnostics mentioned in the filing?

The filing lists Bluejay Diagnostics’ principal executive offices at 360 Massachusetts Avenue, Suite 203, Acton, MA 01720. This address is provided in the description of the issuer’s common stock and its corporate headquarters location in the ownership disclosure.

What voting and dispositive power do the reporting persons retain over BJDX shares after this amendment?

After the amendment, both Braeden Lichti and Northstrive Fund II LP report 0 shares for sole or shared voting power and 0 shares for sole or shared dispositive power, indicating they no longer control any Bluejay Diagnostics common stock.